Although great progresses have been made in the diagnosis and treatment of hepatocellular carcinoma (HCC), its prognostic marker remains controversial. In this current study, weighted correlation network analysis and Cox regression analysis showed significant prognostic value of five autophagy-related long non-coding RNAs (AR-lncRNAs) (including TMCC1-AS1, PLBD1-AS1, MKLN1-AS, LINC01063, and CYTOR) for HCC patients from data in The Cancer Genome Atlas. By using them, we constructed a five-AR-lncRNA prognostic signature, which accurately distinguished the high- and low-risk groups of HCC patients. All of the five AR lncRNAs were highly expressed in the high-risk group of HCC patients. This five-AR-lncRNA prognostic signature showed good area under the curve (AUC) value (AUC = 0.751) for the overall survival (OS) prediction in either all HCC patients or HCC patients stratified according to several clinical traits. A prognostic nomogram with this five-AR-lncRNA signature predicted the 3- and 5-year OS outcomes of HCC patients intuitively and accurately (concordance index = 0.745). By parallel comparison, this five-AR-lncRNA signature has better prognosis accuracy than the other three recently published signatures. Furthermore, we discovered the prediction ability of the signature on therapeutic outcomes of HCC patients, including chemotherapy and immunotherapeutic responses. Gene set enrichment analysis and gene mutation analysis revealed that dysregulated cell cycle pathway, purine metabolism, and TP53 mutation may play an important role in determining the OS outcomes of HCC patients in the high-risk group. Collectively, our study suggests a new five-AR-lncRNA prognostic signature for HCC patients.

尽管在肝细胞癌（HCC）的诊断和治疗方面已取得了很大进展，但其预后指标仍存在争议。在本研究中，加权相关网络分析和Cox回归分析显示了五个自噬相关的长非编码RNA（AR-lncRNA）（包括TMCC1-AS1，PLBD1-AS1，MKLN1-AS，LINC01063和CYTOR）具有显着的预后价值）从癌症基因组图谱中获得的数据用于HCC患者。通过使用它们，我们构建了五个AR-lncRNA的预后标记，可以准确地区分HCC患者的高危和低危人群。在高风险的HCC患者组中，所有五个AR lncRNA均高表达。这五个AR-lncRNA的预后标志显示曲线下（AUC）值下的良好区域（AUC = 0。751），以根据所有临床特征对所有HCC患者或HCC患者进行总体生存（OS）预测。具有这五个AR-lncRNA签名的预后诺模图可以直观，准确地预测HCC患者的3年和5年OS结局（一致性指数= 0.745）。通过并行比较，该五个AR-lncRNA签名比其他三个最近发布的签名具有更好的预后准确性。此外，我们发现了签名对肝癌患者治疗结果的预测能力，包括化疗和免疫治疗反应。基因集富集分析和基因突变分析表明，细胞周期通路失调，嘌呤代谢和TP53突变可能在确定高危组HCC患者OS结局中起重要作用。总的来说，